X4 Pharmaceuticals

: X4 Pharmaceuticals is a commercial-stage biopharmaceutical company headquartered in Boston, Massachusetts. The company employs 40 people and generates approximately $50 million in annual revenue. X4 Pharmaceuticals is focused on developing therapies for rare diseases of the immune system. Their lead product, mavorixafor, has received FDA approval under the brand name XOLREMDI™ for its first indication and is currently being launched in the United States. The company is also advancing mavorixafor for other rare disease populations and plans to begin a pivotal, global Phase 3 clinical trial in people with chronic neutropenic disorders. The company leverages its expertise in CXCR4 and immune system biology to develop patient-centric therapies. Research and development efforts are conducted at both the corporate headquarters in Boston and a research center of excellence in Vienna, Austria. For more information about X4 Pharmaceuticals, please visit their website at x4pharma.com.